Sympathetic Activation in Heart Failure and Its Treatment With β-Blockade | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Cowie  MRMosterd  AWood  DA  et al.  The epidemiology of heart failure.  Eur Heart J. 1997;18208- 225Google ScholarCrossref
2.
Swedberg  KEneroth  PKjekshus  JWilhelmsen  L Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group.  Circulation. 1990;821730- 1736Google ScholarCrossref
3.
Cohn  JNLevine  TBOlivari  MT  et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.  N Engl J Med. 1984;311819- 823Google ScholarCrossref
4.
Kaye  DMLefkovits  JJennings  GLBergin  PBroughton  AEsler  MD Adverse consequences of high sympathetic nervous activity in the failing human heart.  J Am Coll Cardiol. 1995;261257- 1263Google ScholarCrossref
5.
Waagstein  FBristow  MRSwedberg  K  et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.  Lancet. 1993;3421441- 1446Google ScholarCrossref
6.
CIBIS Investigators and Committees, A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS).  Circulation. 1994;901765- 1773Google ScholarCrossref
7.
Australia/New Zealand Heart Failure Research Collaborative Group, Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.  Lancet. 1997;349375- 380Google ScholarCrossref
8.
Packer  MBristow  MRCohn  JN  et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group.  N Engl J Med 1996;3341349- 1355Google ScholarCrossref
9.
Packer  M How should physicians view heart failure? the philosophical and physiological evolution of three conceptual models of the disease.  Am J Cardiol 1993;713C- 11CGoogle ScholarCrossref
10.
Packer  M The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.  J Am Coll Cardiol. 1992;20248- 254Google ScholarCrossref
11.
Cohn  JNArchibald  DGZiesche  S  et al.  Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study.  N Engl J Med. 1986;3141547- 1552Google ScholarCrossref
12.
Packer  MCarver  JRRodeheffer  RJ  et al.  Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group.  N Engl J Med. 1991;3251468- 1475Google ScholarCrossref
13.
Mancia  G Neurohumoral activation in congestive heart failure.  Am Heart J. 1990;1201532- 1537Google ScholarCrossref
14.
Leimbach  WN  JrWallin  BGVictor  RGAylward  PESundlof  GMark  AL Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.  Circulation. 1986;73913- 919Google ScholarCrossref
15.
Genest  JGranger  PDe Champlain  JBoucher  R Endocrine factors in congestive heart failure.  Am J Cardiol. 1968;2235- 42Google ScholarCrossref
16.
Dzau  VJColucci  WSHollenberg  NKWilliams  GH Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.  Circulation. 1981;63645- 651Google ScholarCrossref
17.
Hirsch  ATPinto  YMSchunkert  HDzau  VJ Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure.  Am J Cardiol. 1990;6622D- 30DGoogle ScholarCrossref
18.
Kabour  AHenegar  JRJanicki  JS Angiotensin II (AII)–induced myocyte necrosis: role of the AII receptor.  J Cardiovasc Pharmacol. 1994;23547- 553Google ScholarCrossref
19.
van Zwieten  PAde Jonge  A Interaction between the adrenergic and renin-angiotensin-aldosterone-systems.  Postgrad Med J. 1986;62(suppl 1)23- 27Google ScholarCrossref
20.
Nakamaru  MJackson  EKInagami  T Beta-adrenoceptor-mediated release of angiotensin II from mesenteric arteries.  Am J Physiol. 1986;250H144- H148Google Scholar
21.
The CONSENSUS Trial Study Group, Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).  N Engl J Med. 1987;3161429- 1435Google ScholarCrossref
22.
The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.  N Engl J Med. 1991;325293- 302Google ScholarCrossref
23.
Cohn  JNJohnson  GZiesche  S  et al.  A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure.  N Engl J Med. 1991;325303- 310Google ScholarCrossref
24.
Riegger  GALiebau  GKochsiek  K Antidiuretic hormone in congestive heart failure.  Am J Med. 1982;7249- 52Google ScholarCrossref
25.
Goldsmith  SRFrancis  GSCowley  AW  JrLevine  TBCohn  JN Increased plasma arginine vasopressin levels in patients with congestive heart failure.  J Am Coll Cardiol. 1983;11385- 1390Google ScholarCrossref
26.
Brooks  VLKeil  LCReid  IA Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs.  Circ Res. 1986;58829- 838Google ScholarCrossref
27.
Pacher  RBergler-Klein  JGlobits  S  et al.  Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension.  Am J Cardiol. 1993;711293- 1299Google ScholarCrossref
28.
Kiowski  WSutsch  GHunziker  P  et al.  Evidence for endothelin-1–mediated vasoconstriction in severe chronic heart failure.  Lancet. 1995;346732- 736Google ScholarCrossref
29.
Pacher  RStanek  BHulsmann  M  et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure.  J Am Coll Cardiol. 1996;27633- 641Google ScholarCrossref
30.
Kaddoura  SPoole-Wilson  PA Endothelin-1 in heart failure: a new therapeutic target?  Lancet. 1996;348418- 419Google ScholarCrossref
31.
Brandt  RRWright  RSRedfield  MMBurnett  JC  Jr Atrial natriuretic peptide in heart failure.  J Am Coll Cardiol. 1993;22(suppl A)86A- 92AGoogle ScholarCrossref
32.
Raine  AEErne  PBurgisser  E  et al.  Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure.  N Engl J Med. 1986;315533- 537Google ScholarCrossref
33.
Francis  GSBenedict  CJohnstone  DE  et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD).  Circulation. 1990;821724- 1729Google ScholarCrossref
34.
Floras  JS Sympathoinhibitory effects of atrial natriuretic factor in normal humans.  Circulation. 1990;811860- 1873Google ScholarCrossref
35.
McMurray  JJSeidelin  PHBrown  RAStruthers  AD Noradrenaline attenuates the natriuretic effect of atrial natriuretic factor in man.  Br J Clin Pharmacol. 1989;277- 12Google ScholarCrossref
36.
Nakamura  MYoshida  HMakita  SArakawa  NNiinuma  HHiramori  K Potent and long-lasting vasodilatory effects of adrenomedullin in humans: comparisons between normal subjects and patients with chronic heart failure.  Circulation. 1997;951214- 1221Google ScholarCrossref
37.
Nishikimi  TSaito  YKitamura  K  et al.  Increased plasma levels of adrenomedullin in patients with heart failure.  J Am Coll Cardiol. 1995;261424- 1431Google ScholarCrossref
38.
Andreis  PGNeri  GPrayer-Galetti  T  et al.  Effects of adrenomedullin on the human adrenal glands: an in vitro study.  J Clin Endocrinol Metab. 1997;821167- 1170Google ScholarCrossref
39.
Hasking  GJEsler  MDJennings  GLBurton  DJohns  JAKorner  PI Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity.  Circulation. 1986;73615- 621Google ScholarCrossref
40.
Kaye  DMLefkovits  JCox  H  et al.  Regional epinephrine kinetics in human heart failure: evidence for extra-adrenal, nonneural release.  Am J Physiol. 1995;269H182- H188Google Scholar
41.
Floras  JS Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure.  J Am Coll Cardiol. 1993;22(suppl A)72A- 84AGoogle ScholarCrossref
42.
Hirsch  ATDzau  VJCreager  MA Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance.  Circulation. 1987;75IV36- IV48Google Scholar
43.
Grassi  GSeravalle  GCattaneo  BM  et al.  Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure.  Circulation. 1995;923206- 3211Google ScholarCrossref
44.
Zucker  IHWang  WBrandle  MSchultz  HDPatel  KP Neural regulation of sympathetic nerve activity in heart failure.  Prog Cardiovasc Dis. 1995;37397- 414Google ScholarCrossref
45.
Ellenbogen  KAMohanty  PKSzentpetery  SThames  MD Arterial baroreflex abnormalities in heart failure: reversal after orthotopic cardiac transplantation.  Circulation. 1989;7951- 58Google ScholarCrossref
46.
Gilbert  EMOlsen  SLRenlund  DGBristow  MR Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy.  Am J Cardiol. 1993;7123C- 29CGoogle ScholarCrossref
47.
Bristow  MRAnderson  FLPort  JD  et al.  Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.  Circulation. 1991;841024- 1039Google ScholarCrossref
48.
Woodley  SLGilbert  EMAnderson  JL  et al.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.  Circulation. 1991;842426- 2441Google ScholarCrossref
49.
Francis  GSMcDonald  KMCohn  JN Neurohumoral activation in preclinical heart failure: remodeling and the potential for intervention.  Circulation. 1993;87(suppl)IV90- IV96Google Scholar
50.
Mann  DLKent  RLParsons  BCooper  G  IV Adrenergic effects on the biology of the adult mammalian cardiocyte.  Circulation. 1992;85790- 804Google ScholarCrossref
51.
Meredith  ITBroughton  AJennings  GLEsler  MD Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias.  N Engl J Med. 1991;325618- 624Google ScholarCrossref
52.
Olsson  GRehnqvist  N Ventricular arrhythmias during the first year after acute myocardial infarction: influence of long-term treatment with metoprolol.  Circulation. 1984;691129- 1134Google ScholarCrossref
53.
Maisel  AS Beneficial effects of metoprolol treatment in congestive heart failure: reversal of sympathetic-induced alterations of immunologic function.  Circulation. 1994;901774- 1780Google ScholarCrossref
54.
Stephen  SA Unwanted effects of propranolol.  Am J Cardiol. 1966;18463- 472Google ScholarCrossref
55.
Feuerstein  GZRuffolo  RR  Jr Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.  Eur Heart J. 1996;17(suppl B)24- 29Google ScholarCrossref
56.
Eichhorn  EJ Effects of bucindolol in heart failure.  Am J Cardiol. 1993;7165C- 70CGoogle ScholarCrossref
57.
Gilbert  EMAbraham  WTOlsen  S  et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.  Circulation. 1996;942817- 2825Google ScholarCrossref
58.
Waagstein  FHjalmarson  AVarnauskas  EWallentin  I Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.  Br Heart J. 1975;371022- 1036Google ScholarCrossref
59.
Heilbrunn  SMShah  PValentine  HA  et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during chronic metoprolol therapy [abstract].  Circulation. 1986;74(suppl 2)II- 310Google Scholar
60.
Fowler  MBBristow  MRLaser  JAGinsburg  RScott  LBSchroeder  JS Beta-blocker therapy in severe heart failure: improvement related to β1-adrenergic receptor up-regulation [abstract]?  Circulation. 1984;70(suppl 2)II- 112Google Scholar
61.
Heidenreich  PALee  TTMassie  BM Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials.  J Am Coll Cardiol. 1997;3027- 34Google ScholarCrossref
62.
Pfeffer  MAStevenson  LW Beta-adrenergic-blockers and survival in heart failure.  N Engl J Med. 1996;3341396- 1397Google ScholarCrossref
63.
The BEST Steering Committee, Design of the Beta-Blocker Evaluation Survival Trial (BEST).  Am J Cardiol. 1995;751220- 1223Google ScholarCrossref
64.
Not Available, Physicians' Desk Reference. 52nd ed. Montvale, NJ Medical Economics Co1998;2810
65.
Bristow  MRGilbert  EMAbraham  WT  et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators.  Circulation. 1996;942807- 2816Google ScholarCrossref
Review
February 8, 1999

Sympathetic Activation in Heart Failure and Its Treatment With β-Blockade

Author Affiliations

From the Division of Cardiovascular Diseases, Mayo Clinic Scottsdale, Scottsdale, Ariz.

Arch Intern Med. 1999;159(3):225-234. doi:10.1001/archinte.159.3.225
Abstract

Multiple models explaining the pathogenesis of heart failure have been put forth during the past 5 decades. These models were modified as clinical evidence supported or refuted their assumptions. During the past 2 decades, heart failure models emphasized the importance of neurohormonal systems in heart failure progression. The positive impact that angiotensin-converting enzyme inhibitors have had on mortality from heart failure has bolstered the neurohormonal theory. Attention recently has turned to the sympathetic nervous system and its potential deleterious effects on the cardiovascular system in heart failure. The sympathetic nervous system can negatively impact the cardiovascular system in heart failure in several ways, including down-regulating β1-receptors, exerting direct toxic effects on the myocardium, and contributing to myocardial remodeling and life-threatening arrhythmias. β-Adrenergic blockers have shown promise for reducing morbidity and mortality in heart failure, but definitive reductions in mortality remain to be shown by future investigations.

×